Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.

Inclusion Criteria: * Female or male, and any race, Age ≥ 18 years and≤ 65 outpatients. * Gastroenterologists already prescribe PPI standard dose bid as empirical treatment. * GerdQ≥8 * The subject will not have endoscopy within 4 weeks after enrolment. * Ability to provide informed consent, adhere to the study visit schedule, and complete all study assessments and complete the patient diary by his/herself. Exclusion Criteria: * If participating in any interventional clinical trial. * Patient with alarm symptom of oncology(weight loss, recurrent dysphagia, anemia, hematemesis, melena). * Continuous application of nonsteroidal anti-inflammation drugs or acid suppressive drug within 2 weeks before screening. * The need for H2-receptor antagonists (H2RA) including cimetidine, ranitidine and famotidine or sucralfate, antacids, traditional Chinese medicine and prokinetics during the upcoming 4 weeks (study duration). * Previous gastroesophageal surgery. * Upper gastrointestinal malignancy, achalasia, and esophageal spasm or stricture. * Peptic ulcer * Diabetes * Cerebral vascular disease * Zollinger-Ellison syndrome * Scleroderma * Hiatus hernia women * Pregnant or lactating women * Any other subjects were not suitable to this study in the opinion of the investigator.